WallStreetZenWallStreetZen

NASDAQ: PMCB
Pharmacyte Biotech Inc Stock

$2.06+0.01 (+0.49%)
Updated Jul 17, 2024
PMCB Price
$2.06
Fair Value Price
$3.49
Market Cap
$17.44M
52 Week Low
$1.76
52 Week High
$2.89
P/E
-1.72x
P/B
0.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.14M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.72
Operating Cash Flow
-$2M
Beta
0.23
Next Earnings
Jul 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PMCB Overview

PharmaCyte Biotech, Inc. is developing cellular therapies for cancer and diabetes in the U.S. Its therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology. Formerly Nuvilex, Inc., PharmaCyte Biotech was incorporated in 1996 and is headquartered in Laguna Hills, CA.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PMCB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PMCB ($2.06) is undervalued by 40.99% relative to our estimate of its Fair Value price of $3.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PMCB ($2.06) is significantly undervalued by 40.99% relative to our estimate of its Fair Value price of $3.49 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PMCB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PMCB due diligence checks available for Premium users.

Be the first to know about important PMCB news, forecast changes, insider trades & much more!

PMCB News

Valuation

PMCB fair value

Fair Value of PMCB stock based on Discounted Cash Flow (DCF)
Price
$2.06
Fair Value
$3.49
Undervalued by
40.99%
PMCB ($2.06) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PMCB ($2.06) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PMCB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PMCB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.72x
Industry
-21.17x
Market
30.24x

PMCB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.56x
Industry
6.35x
PMCB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PMCB's financial health

Profit margin

Revenue
$0.0
Net Income
-$619.5k
Profit Margin
0%
PMCB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$71.4M
Liabilities
$22.5M
Debt to equity
0.72
PMCB's short-term assets ($61.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMCB's short-term assets ($61.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMCB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PMCB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$177.1k
Investing
-$5.0M
Financing
-$7.0M
PMCB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PMCB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PMCB$17.44M+0.49%-1.72x0.56x
KZIA$17.37M+15.21%-1.80x5.01x
SNSE$17.63M-2.36%-0.58x0.30x
BCTX$16.84M-5.83%-2.49x-2.82x
CMMB$16.64M+4.46%-0.75x1.25x

Pharmacyte Biotech Stock FAQ

What is Pharmacyte Biotech's quote symbol?

(NASDAQ: PMCB) Pharmacyte Biotech trades on the NASDAQ under the ticker symbol PMCB. Pharmacyte Biotech stock quotes can also be displayed as NASDAQ: PMCB.

If you're new to stock investing, here's how to buy Pharmacyte Biotech stock.

What is the 52 week high and low for Pharmacyte Biotech (NASDAQ: PMCB)?

(NASDAQ: PMCB) Pharmacyte Biotech's 52-week high was $2.89, and its 52-week low was $1.76. It is currently -28.72% from its 52-week high and 17.05% from its 52-week low.

How much is Pharmacyte Biotech stock worth today?

(NASDAQ: PMCB) Pharmacyte Biotech currently has 8,464,824 outstanding shares. With Pharmacyte Biotech stock trading at $2.06 per share, the total value of Pharmacyte Biotech stock (market capitalization) is $17.44M.

Pharmacyte Biotech stock was originally listed at a price of $57.35 in Jan 2, 2013. If you had invested in Pharmacyte Biotech stock at $57.35, your return over the last 11 years would have been -96.41%, for an annualized return of -26.1% (not including any dividends or dividend reinvestments).

How much is Pharmacyte Biotech's stock price per share?

(NASDAQ: PMCB) Pharmacyte Biotech stock price per share is $2.06 today (as of Jul 17, 2024).

What is Pharmacyte Biotech's Market Cap?

(NASDAQ: PMCB) Pharmacyte Biotech's market cap is $17.44M, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pharmacyte Biotech's market cap is calculated by multiplying PMCB's current stock price of $2.06 by PMCB's total outstanding shares of 8,464,824.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.